Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity
NCT07135141Not yet recruiting
- Sponsor
- Beijing Friendship Hospital
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Hormonal Peptides
- Countries
- 1
01
Overview
Randomised, double-blind trial in obesity comparing Sleeve gastrectomy plus mazdutide with Sleeve gastrectomy plus placebo (2 arms). Primary endpoint: Excess Weight Loss at 48 weeks. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
mazdutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07135141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07135141.